Key Analysts at Robert W. Baird Kept their ‘”Buy”’ rating for PRA Health Sciences (NASDAQ:PRAH) Shares Today. Their Price Objective Given is $94.0

March 14, 2018 - By Nellie Frank

 Key Analysts at Robert W. Baird Kept their ‘

PRA Health Sciences (NASDAQ:PRAH) Rating Reaffirmed

Analysts at Robert W. Baird now has a $94.0 PT on PRA Health Sciences (NASDAQ:PRAH). Robert W. Baird and their recent PT gives a potential upside of 3.64 % from the company’s close price. The rating has been shown in a research note on Thursday morning.

PRA Health Sciences, Inc. (NASDAQ:PRAH) Ratings Coverage

Among 15 analysts covering PRA Health Sciences (NASDAQ:PRAH), 10 have Buy rating, 0 Sell and 5 Hold. Therefore 67% are positive. PRA Health Sciences has $110.0 highest and $43 lowest target. $92.08’s average target is 1.52% above currents $90.7 stock price. PRA Health Sciences had 42 analyst reports since July 22, 2015 according to SRatingsIntel. On Friday, August 14 the stock rating was reinitiated by Credit Suisse with “Outperform”. The firm earned “Buy” rating on Thursday, September 22 by Citigroup. As per Monday, February 27, the company rating was upgraded by Avondale. The firm earned “Buy” rating on Wednesday, May 4 by Citigroup. The stock of PRA Health Sciences, Inc. (NASDAQ:PRAH) earned “Buy” rating by SunTrust on Monday, February 26. The firm earned “Outperform” rating on Thursday, October 26 by Credit Suisse. Jefferies maintained it with “Buy” rating and $97.0 target in Friday, October 27 report. The stock has “Neutral” rating by UBS on Tuesday, September 6. The firm has “Buy” rating by Credit Suisse given on Monday, October 16. Credit Suisse initiated PRA Health Sciences, Inc. (NASDAQ:PRAH) on Tuesday, June 21 with “Neutral” rating.

The stock decreased 1.59% or $1.47 during the last trading session, reaching $90.7. About 389,012 shares traded. PRA Health Sciences, Inc. (NASDAQ:PRAH) has risen 52.22% since March 14, 2017 and is uptrending. It has outperformed by 35.52% the S&P500.

Analysts await PRA Health Sciences, Inc. (NASDAQ:PRAH) to report earnings on April, 24. They expect $0.77 earnings per share, up 28.33 % or $0.17 from last year’s $0.6 per share. PRAH’s profit will be $49.12 million for 29.45 P/E if the $0.77 EPS becomes a reality. After $1.04 actual earnings per share reported by PRA Health Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.96 % negative EPS growth.

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company has market cap of $5.79 billion. The firm offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It has a 68.71 P/E ratio. It also provides product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

More recent PRA Health Sciences, Inc. (NASDAQ:PRAH) news were published by: which released: “PRA Health Sciences Named Best CRO in Asia” on March 06, 2018. Also published the news titled: “PRA Health Sciences Receives CRO Leadership Award” on March 14, 2018.‘s news article titled: “Pre-Market Technical Scan on Medical Research Equities — HTG Molecular …” with publication date: March 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: